Who are the top investors in MedTech?

Whether you're building or investing in the medtech market, our report covers everything you need to know: the players, the money, and what's coming next.

Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us

Who are the biggest MedTech investors today?

OrbiMed, Sofinnova Partners, Vensana Capital, NEA, and Deerfield Management are among the biggest names in MedTech investing today, although Sofinnova and Vensana stand out when we focus specifically on medical devices rather than healthcare as a whole.

OrbiMed and Deerfield have large healthcare investment platforms spanning pharmaceuticals, biotechnology, medical devices, and diagnostics. NEA has decades of experience financing healthcare companies. Sofinnova combines medical technology company creation with larger venture investments, while Vensana concentrates almost entirely on medical technology.

Other important investors include Gilde Healthcare, EQT Life Sciences, HealthQuest Capital, Lightstone Ventures, Arboretum Ventures, and Revival Healthcare Capital.

The distinction between healthcare investing and MedTech investing makes a surprisingly big difference. A firm managing billions in pharmaceutical investments may have less direct experience helping a surgical device reach the market than a much smaller medical technology specialist.

To identify the strongest investors, we examined their actual medical technology investments, fund sizes, involvement in major rounds, company-building activities, and portfolio exits. We gave particular weight to repeated involvement rather than individual headline transactions.

If you want more recent data on this point, please see our latest MedTech market report.

Why are investors putting more money into MedTech again?

Investors are putting more money into MedTech because the sector is attracting larger financing rounds and more strategic acquisitions, although much of the recovery is concentrated in relatively few companies.

According to HSBC Innovation Banking's 2026 midyear healthcare report, US medical device investment remained above 2023 and 2024 levels during the first half of 2026. There were 24 financings worth at least $50 million, with notable activity in neurotechnology, imaging, and non-invasive monitoring.

EY's 2026 Pulse of the MedTech Industry report offers an even bigger number: MedTech financing reached approximately $63 billion over the twelve months ending June 2026, up 87% year over year.

That sounds like a venture capital boom, but around 80% of the total came from debt and public equity financing. Much of the money went to established businesses rather than startups.

The difference becomes clearer when we examine venture investment separately. EY's 2025 report found that venture financing had risen 20% to $8.7 billion during its reporting period, while the number of rounds fell 47% to 237. Larger average deals were making up for fewer transactions.

The more recent HSBC data also suggests that the recovery is spreading beyond late-stage companies. First financings increased during the first half of 2026, helped by Series A rounds exceeding $20 million.

Two developments are happening together: investors are writing larger checks for companies that have already made progress, while early-stage financing is beginning to recover. Both favor specialist funds capable of deciding which technologies deserve years of additional investment.

In our report covering the medtech market, you will always find fresh funding data, taken straight from our own verified funding database.

Is OrbiMed really the number-one MedTech investor?

OrbiMed is among the most powerful healthcare investors in the world, but we would not call it the undisputed number-one medical device investor.

The firm invests across pharmaceuticals, biotechnology, medical devices, diagnostics, and healthcare services. Its global investment platform gives it access to companies at different stages, from private startups to publicly traded healthcare businesses.

That flexibility is valuable in MedTech. A company developing a cardiac implant might need several financing rounds before generating meaningful revenue. An investor with experience across private and public healthcare markets can potentially support different stages of that journey.

OrbiMed also benefits from decades of healthcare investment experience and relationships with clinical researchers, executives, and larger industry players.

Yet its scale creates a problem for rankings. Total healthcare assets include substantial exposure to businesses outside medical devices. Comparing those assets directly with Vensana's dedicated MedTech funds would make OrbiMed look more dominant in medical technology than the evidence supports.

We place OrbiMed in the top tier for overall healthcare investment resources and reach. For founders seeking investors whose portfolios are concentrated almost entirely on medical devices, Vensana and several other specialists offer a more direct match.

If you want more recent data on this point, please see our latest MedTech market report.

Is Sofinnova Partners the best investor for new MedTech startups?

Sofinnova Partners has one of the strongest claims to leadership in early-stage MedTech investing, especially when a company is still being created.

Its MD Start program develops medical technology companies from their earliest stages. In September 2026, Sofinnova announced the final close of MD Start IV at €82 million, with plans to create six to eight companies over the following five years.

The previous fund invested in six businesses that subsequently raised more than €140 million in follow-on financing. That works out to more than €23 million per company on average, although the amounts were not necessarily distributed equally.

The history behind MD Start is more revealing than the new fundraising announcement. LimFlow developed technology designed to help patients with severe peripheral artery disease avoid amputations. Inari Medical acquired the company in 2023 for potential consideration of up to $415 million. PreCARDIA, which worked on heart failure treatment, was acquired by Abiomed.

Moon Surgical provides a different example. Its Maestro surgical assistance system obtained regulatory clearance, and Sofinnova reported in September 2026 that the technology had been used to treat more than 3,700 patients.

These companies show three stages of the same strategy: creating a business, financing clinical development, and eventually reaching patients or attracting an acquirer.

Sofinnova also manages larger investment strategies. Its €650 million Capital XI fund, announced in November 2025, finances biotechnology and medical technology companies across Europe and the United States.

Few MedTech investors have such a visible combination of company creation and later-stage financing. For startups developing new medical devices from scratch, we would place Sofinnova near the very top.

In our research about medical devices, we turn what is vague and complex into simple, useful visuals. Market maps like this one show you at a glance where every startup stands.

Is Vensana Capital the strongest specialist MedTech investor?

Vensana Capital is one of the best candidates for the strongest dedicated MedTech venture investor today, particularly for companies developing or commercializing medical devices.

Founded in 2019 by Kirk Nielsen and Justin Klein, Vensana closed its third fund at $425 million in January 2025. The firm now manages approximately $1 billion, having previously raised funds of $225 million and $325 million.

Across its three funds, Vensana has secured approximately $975 million in commitments. Its latest fund is about 89% larger than its first, showing how much its fundraising capacity has grown since launch.

The firm typically invests $15 million to $50 million per company. Those commitments are substantial enough to support major clinical studies, regulatory work, and commercial expansion.

Its concentration is what makes Vensana particularly interesting. Unlike OrbiMed or Deerfield, the firm focuses directly on medical devices, diagnostics, and clinically oriented data science businesses.

Vensana has also established Vensana Innovation, a company-building initiative that combines financing with technical, clinical, commercial, and business development expertise.

This gives the firm influence earlier in the development of medical technologies, although its main investment strategy remains centered on development-stage and commercial-stage companies.

Vensana's main limitation in a historical ranking is its age. A firm founded in 2019 cannot yet match the decades of realized investment history available for some established healthcare funds. But for specialist focus, meaningful financing capacity, and current relevance, it belongs in the first group of investors we would examine.

If you want more recent data on this point, please see our latest MedTech market report.

Which MedTech investors are leading the biggest funding rounds?

Revival Healthcare Capital, Sofinnova Partners, MVM Partners, and EQT Life Sciences are among the MedTech investors with clear evidence of leading substantial recent device financings.

Revival Healthcare Capital led Distalmotion's $150 million Series G in November 2025. The Swiss company develops the DEXTER surgical robotics system, and the financing was intended largely to support its US commercial expansion.

Sofinnova led Galvanize Therapeutics' $100 million Series C in September 2025, backing pulsed electric field technologies for cancer and chronic lung disease. It also co-led HighLife's financing of more than $90 million in September 2026, alongside Andera Partners, Supernova Invest, and Mérieux Equity Partners.

MVM Partners led Neurent Medical's €62.5 million Series C in February 2026. Neurent develops a radiofrequency treatment for chronic rhinitis, a condition affecting the nasal passages.

EQT Life Sciences led a $56 million Series D for Neuros Medical in 2025. The company develops neurostimulation technology for people experiencing chronic pain following an amputation.

Together, these five financings represent more than $460 million in announced capital before currency conversion adjustments. These are total syndicate rounds, not amounts personally invested by their lead investors.

The transactions cover surgical robotics, pulsed electric field treatments, structural heart intervention, ear-nose-throat procedures, and neurostimulation.

Large device rounds are appearing across several clinical fields rather than being confined to one fashionable technology. A fund's position in a particular specialty can be more informative than its place in a broad industry ranking.

In our market report about medical devices, we always try to gather several sources and make estimates that make sense, so you can work with solid numbers.

Which MedTech investors have made the most successful exits?

HealthQuest Capital, Sofinnova Partners, Gilde Healthcare, and Lightstone Ventures have some of the clearest publicly visible MedTech portfolio successes, although we cannot rank their financial returns without private fund data.

HealthQuest Capital offers two particularly strong examples. HistoSonics, developer of the Edison histotripsy system for destroying tissue using focused ultrasound, announced a management-led majority stake transaction in August 2025 at an enterprise valuation of approximately $2.25 billion.

HealthQuest also backed OrganOx, a company developing organ preservation technology. Terumo announced an agreement to acquire OrganOx in August 2025 and completed the transaction in October for approximately $1.5 billion.

Gilde Healthcare's portfolio includes Inari Medical, acquired by Stryker in 2025 for approximately $4.9 billion. Inari developed devices for treating blood clots, making it an important example of how specialized vascular technologies can attract large strategic buyers.

Sofinnova's record includes the acquisitions of LimFlow and PreCARDIA. Lightstone Ventures backed Relievant Medsystems, acquired by Boston Scientific in 2023, and Shoulder Innovations, which completed an IPO in July 2025.

These outcomes cover vascular intervention, organ preservation, cancer treatment, spine procedures, and orthopedic implants. Successful MedTech investing clearly extends beyond the categories attracting the most attention today.

There is an important limit to what we can conclude. A $2 billion acquisition does not reveal how much an early investor earned. We would need its ownership percentage, investment cost, dilution history, and actual proceeds.

We can confidently identify these firms as investors associated with important MedTech exits. Determining which produced the highest net return would require financial information that most private funds do not publish.

If you want more recent data on this point, please see our latest MedTech market report.

Does managing more money make Deerfield a better MedTech investor than Vensana?

Deerfield Management has far more financial resources than Vensana Capital, but Vensana's dedicated medical technology strategy can make it a better match for a device startup.

Deerfield reported more than $16 billion in assets under management as of December 2025, across a healthcare portfolio spanning therapeutics, diagnostics, medical devices, digital health, and healthcare services.

Vensana manages approximately $1 billion. That means Deerfield's reported asset base is more than sixteen times larger, though these assets cover very different strategies.

A startup should care about how much capital an investor can actually commit to its particular technology.

Vensana publicly reports typical commitments of $15 million to $50 million, giving founders a relatively clear indication of its financing range. Deerfield offers a much broader set of healthcare financing approaches and can support transactions that extend beyond conventional venture capital.

The most relevant comparison therefore depends on the company. Vensana is an obvious candidate for a medical device business preparing a significant clinical or commercial financing round. Deerfield may be more attractive when a company needs a broader or more complex financing structure.

Size still matters, particularly for companies facing expensive clinical programs. But a large asset base alone tells us surprisingly little about an investor's actual involvement in medical technology.

Our document detailing everything you need to know about medtech gets updated several times a month, so you always get the latest view of where things stand.

Who are the leading MedTech investors in Europe?

Sofinnova Partners, Gilde Healthcare, EQT Life Sciences, Andera Partners, and MVM Partners are among Europe's most important MedTech investors, with Sofinnova particularly prominent in early-stage company creation.

Sofinnova's €82 million MD Start IV and €650 million Capital XI funds provide two different ways to finance medical technologies. The first focuses on creating companies; the second supports a broader life sciences portfolio across Europe and the United States.

Gilde Healthcare has invested in businesses including Inari Medical, Fire1, ProVerum, and Withings. The firm invests across European and North American healthcare markets and can make equity commitments of up to €50 million per portfolio company.

EQT Life Sciences brings another substantial platform, reporting approximately €3.5 billion raised across twelve funds. Its medical technology investments include Neuros Medical, Cyted Health, and Xeltis.

MVM Partners led Neurent Medical's €62.5 million financing in February 2026, while Andera Partners co-led HighLife's financing exceeding $90 million in September 2026.

The geographic pattern is worth examining. HighLife is using its latest funding to support US clinical development and European commercial expansion. Neurent is financing commercialization of its chronic rhinitis treatment, while other European device businesses are using international capital to reach larger healthcare markets.

European MedTech investors often need to help companies operate across different regulatory, reimbursement, and commercial environments. The strongest firms have experience financing that international transition.

Sofinnova, Gilde, and EQT Life Sciences are therefore especially relevant to founders planning to develop technology in Europe and eventually expand into the United States.

If you want more recent data on this point, please see our latest MedTech market report.

In our report covering the medtech market, we look at what the winners do differently, so you can learn from the best instead of guessing.